Research programme: leptin receptor antagonist - BioLineRx

Drug Profile

Research programme: leptin receptor antagonist - BioLineRx

Alternative Names: BL-5040

Latest Information Update: 16 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer BioLineRx
  • Class Adipokines; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Leptin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cachexia; Inflammatory bowel diseases

Most Recent Events

  • 15 Aug 2012 BL 5040 is available for licensing as of 15 Aug 2012. http://www.biolinerx.com
  • 03 Mar 2011 Preclinical development is ongoing in Israel
  • 13 Nov 2008 BL 5040 is licensed to BioLineRx worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top